Drug Watch: Pain
FDA Approves Metastatic Breast Cancer Drug, Datroway
Datroway reduced disease progression by 37% when compared with chemotherapy.
Read More
UnitedHealth Vows to Reduce Prior Authorization Burden
CEO Andrew Witty promised that UnitedHealthcare would work to speed up turnaround times for approval of some procedures and services in Medicare Advantage plans.
CMS Releases Next List for Drug Price Negotiation
Ozempic, Rybelsus and Wegovy top the list of the newest drugs selected for Medicare Part D price negotiation, part of the Inflation Reduction Act.
FDA Approves Lilly’s Omvoh for Crohn's Disease, Second Indication
More than half (53%) of patients reached remission after one year of Omvoh treatment and 46% experienced healing of the intestinal tract, when compared to placebo.
UnitedHealth Group CEO Andrew Witty Defends PBMs
In an investor call, Andrew Witty promised full transparency and 100% pass-through rebates for prescription drugs by 2028.
FDA Accepts BLA for Leqembi Autoinjector
If approved, subcutaneous autoinjector Leqembi will be the only Alzheimer's medication that can be administered at home. The FDA has set a goal date of Aug. 31, 2025.
